PROKIDNEY CORP.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Prokidney
Biological Products, (No Diagnostic Substances), SIC 2836
ProKidney Corp. is a clinical-stage biotechnology company that develops autologous cell therapies to preserve kidney function in individuals suffering from chronic kidney disease and diabetes. Its lead product candidate, rilparencel, uses selected renal cells harvested from a patient's own kidney biopsy, which are processed and reinjected into the damaged organ through a minimally invasive procedure. Operating in a single segment, the company focuses on creating personalized regenerative treatments that eliminate the need for donor immunosuppression. Its end users are patients with advanced chronic kidney disease and diabetes.
The company maintains its principal executive offices in Winston-Salem, North Carolina, and is incorporated in Delaware following a corporate redomestication from the Cayman Islands. Its operational reach spans clinical research centers located across the United States, Mexico, and Taiwan. Additionally, it operates dedicated internal manufacturing facilities to process patient tissue and produce cell therapies.
Summary of the business section of Prokidney's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PROKIDNEY CORP.
- Headquarters
- Winston-Salem, NC
- Address
- 2000 Frontis Plaza Blvd., Suite 250 27103
- Phone
- (336) 999-7028
- Website
- prokidney.com
- Employees
- 231, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Atlanta, Georgia, United States
Stock & identifiers
- Ticker
- PROK
- Exchange
- Nasdaq
- IPO date
- Jul 1, 2021
- Shares outstanding
- 302M, Aug 10, 2026
- Public float
- $58.87M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1850270
- CUSIP
- 74291D104
- ISIN
- US74291D1046
- EIN
- 98-1586514
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Bruce Culleton | Chief Executive Officer, Director | – |
| Kenneth Thomas Locke | Chief Technical Officer | – |
| Todd C. Girolamo | Chief Legal Officer | 327,713 |
| Darin J. Weber | Chief Regulatory Officer | 402,283 |
| James Coulston | Chief Financial Officer | 716,850 |
| Brian JG Pereira | Director | 222,948 |
| Uma Sinha | Director | 30,000 |
| Pablo G. Legorreta | Director | 110,725,335 |
| William F. Doyle | Director | 1,514,326 |
| Alan Lotvin | Director | 1,514,326 |
| Jennifer A. Fox | Director | 0 |
| Santos Jose Ignacio Jimenez | Director | 0 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, ProKidney had 231 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 31, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Aug 12, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 15, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 15, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 12, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 11, 2022 | Name change | Name changed from Social Capital Suvretta Holdings Corp. III to PROKIDNEY CORP. |
| Jun 10, 2022 | Merger vote | Definitive merger proxy statement |
| Jul 1, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 29, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |